· Advanced atrial fibrillation ablation technology with its unique gradient electric field selection feature enables complete myocardial cell ablation without causing complications such as phrenic nerve injury, atrial esophageal fistula, and pulmonary vein stenosis, and has a low postoperative recurrence rate.

· The unique lantern skeleton structure and high-speed discharge mode simplify the surgical procedure and improve the ablation efficiency.

· It owns complete independent intellectual property , has obtained national patent for invention authorization, and has applied for international patents in multiple countries in Europe and Southeast Asia.

· This clinical trial has been approved by the ethics committees of multiple well-known hospitals in China, and is currently undergoing nationwide multicenter clinical trial. We are now recruiting atrial fibrillation patients nationwide.

In 2019,Pulsed Field Ablation Therapeutic Apparatus obtained national certificate of patent for utility model（Figure 1）

In 2021,Pulsed Field Ablation Therapeutic Apparatus obtained national certificate of patent for an invention（Figure 2）

In 2022, Pulsed Field Ablation Therapeutic Apparatus was approved as the first domestically produced PFA product by China’s Innovative Medical Device Special Approval.(Figure 3）